Arkin Bio Launches $100M Early-Stage Fund
Arkin Capital announced today the closing of Arkin Bio Ventures III, a $100 million fund to invest in advanced pre-clinical and early clinical-stage biotech companies. The fund, backed by institutional investors including Phoenix Insurance, Clal Insurance, and Amitim Pension Funds, targets 10–12 companies in oncology, immunology, inflammation, rare diseases and other high unmet-need areas. Led by Dr. Pini Orbach, the fund emphasizes biology-first investing and hands-on translational support to accelerate proof-of-concept.
Key Points
- 1Raised $100M fund to back advanced pre-clinical and early clinical-stage biotech companies
- 2Prioritizes oncology, immunology, inflammation, and rare diseases to address high unmet medical need
- 3Encourages founders to align early with clinical endpoints, facilitating later partnerships and exits
Scoring Rationale
Official $100M fund announcement provides concrete investment signal, but limited novelty and industry-wide impact constrains broader significance.
Sources
Public references used for this report.
Practice interview problems based on real data
1,625 SQL & Python problems across 15 industry datasets — the exact type of data you work with.
Try 250 free problems
